Matthew T. Hall
Matthew T. Hall has more than 12 years of experience in life sciences and healthcare investments as both a direct investor and limited partner. His investment experience spans medical devices, therapeutics, diagnostics, healthcare IT and ag biotech. Mr. Hall specializes in providing capital sourcing, growth and exit strategy solutions to emerging and established life sciences and healthcare companies as well as their sponsoring venture capital and private equity firms.
Mr. Hall is also Managing Partner of Highland Park Partners, a firm he founded in 2016 to provide finance, investment and economic development consulting solutions to venture capital, private equity, non-profit and governmental clients seeking to enhance the innovation economy.
Prior to founding Highland Park Partners, Mr. Hall was a Vice President at The Carlyle Group (NASDAQ: CG) where he was responsible for sourcing, evaluating, and executing fund investment opportunities and leading the life sciences efforts in North America for the firm’s AlpInvest Partners business segment ($40B AUM).
He joined the Carlyle Group from BioCrossroads, where he was Director of Projects and Finance working on project development, capital formation and enterprise investment of BioCrossroads, its entities and initiatives and was a Principal of Indiana Seed Fund II where he was responsible for deal sourcing, diligence and execution of portfolio company investments. He currently serves as a Managing Director of BioCrossroads’ subsequent fund, Indiana Seed Fund III.
Prior to his career in life sciences and healthcare investment, Mr. Hall held investment banking and municipal finance positions negotiating and financing high profile economic development projects. Mr. Hall attended Indiana University where he received a BA in Political Science.